Ethane

Ethane

SCHEMBL1703774

CC.Nc1ccc(F)cc1

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.54
TDP1 Q9NUW8 4/20 0.54
MAPK1 P28482 4/20 0.54
MAPT P10636 2/20 0.54
LMNA P02545 1/20 0.54
HTT P42858 1/20 0.54
GFER P55789 1/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
MAOB P27338 2/20 0.48
ACHE P22303 2/20 0.47
CYP3A4 P08684 3/20 0.44
TP53 P04637 2/20 0.44
TAAR1 Q96RJ0 2/20 0.43
ALOX15 P16050 3/20 0.41
LOXL2 Q9Y4K0 1/20 0.41
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3199 0.93
SCHEMBL28865604 0.93 MAPT (0.61) ALDH1A1TDP1MAPK1MAPTLMNA
SCHEMBL8466839 0.93 MAPT (0.61) ALDH1A1TDP1MAPK1MAPTLMNA
SCHEMBL18867937 0.93
Methyl Alcohol SCHEMBL28245142 0.90 ALDH1A1 (0.52) ALDH1A1TDP1MAPK1MAPTLMNA
Bromide SCHEMBL25172333 0.90
Hydrochloric Acid SCHEMBL3845511 0.90 MAPT (0.57) ALDH1A1TDP1MAPK1MAPTLMNA
SCHEMBL357942 0.90
Hydrochloric Acid SCHEMBL2761740 0.90
Methane SCHEMBL22289599 0.90

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409903-B2 Benzyl substituted triazine derivatives and their therapeutical applications NANTBIOSCIENCE, INC. (US) 2016-08-09 US disclosed
US-20150057285-A1 BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS NANTBIOSCIENCE INC (US) 2015-02-26 US disclosed
US-8877924-B2 Benzyl substituted triazine derivatives and their therapeutical applications NantBio Inc. (US) 2014-11-04 US disclosed
US-20120264759-A1 BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS CALIFORNIA CAPITAL EQUITY, LLC (US) 2012-10-18 US disclosed
EP-2440053-A1 BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS Abraxis BioScience, LLC (US) 2012-04-18 EP disclosed
WO-2010144394-A1 BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS ABRAXIS BIOSCIENCE, LLC (US) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150057285-A1 BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS BAZ2A, BAZ2B, PRKCZ ALDH1A1 4143/4885TDP1 1868/4885MAPK1 407/4885
US-20120264759-A1 BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS BAZ2A, BAZ2B, PRKCZ ALDH1A1 4143/4885TDP1 1868/4885MAPK1 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.